我们的研究旨在评价利妥昔单抗加化疗一线治疗的滤泡性淋巴瘤患者使用利妥昔单抗维持治疗2年的疗效。
We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen.
阐释：滤泡性淋巴瘤患者在免疫化疗作为一线治疗后使用利妥昔单抗维持治疗2年，能显著改善无进展生存（PFS）。
INTERPRETATION: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.
阐释：滤泡性淋巴瘤患者在免疫化疗作为一线治疗后使用利妥昔单抗维持治疗2年，能显著改善无进展生存（PFS）。
INTERPRETATION: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.
应用推荐